Literature DB >> 10584461

Methadone: outpatient titration and monitoring strategies in cancer patients.

N A Hagen1, E Wasylenko.   

Abstract

Methadone can be an effective drug for cancer pain but it can also be difficult to use safely. It has been recommended that rotation to methadone from other opioids be undertaken in a hospital setting. The purpose of the study was to characterize the safety, toxicities, and outcomes of outpatient rotation to methadone for severe cancer pain in a heavily pretreated cohort of cancer patients. Data were collected through a retrospective review of consecutive patients from a tertiary level cancer pain clinic. Twenty-nine patients were rotated to methadone, 13 (45%) due to opioid toxicity and 16 (55%) because of either cost or difficulty swallowing their prior opioid. Eleven of 29 patients (38%) failed methadone due to rapidly progressive cancer, dose-limiting side effects, or other reasons, but the other patients were successfully rotated to methadone. Pain usually improved following rotation to methadone, but drowsiness from methadone was common. On average, it took 32 days to successfully rotate to methadone in the outpatient setting. Cancer patients with advanced disease and severe pain can be safely and effectively rotated to methadone in the outpatient setting. It takes considerably longer to stabilize these patients than patients on lower doses of opioid or those titrated in the inpatient setting. A careful monitoring system is needed to screen for evidence of toxicity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10584461     DOI: 10.1016/s0885-3924(99)00083-4

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  14 in total

Review 1.  Alternative opioids to morphine in palliative care: a review of current practice and evidence.

Authors:  M Barnett
Journal:  Postgrad Med J       Date:  2001-06       Impact factor: 2.401

Review 2.  Methadone for treatment of cancer pain.

Authors:  John Bryson; Anoo Tamber; Dori Seccareccia; Camilla Zimmermann
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

3.  Methadone initiation and rotation in the outpatient setting for patients with cancer pain.

Authors:  Henrique A Parsons; Maxine de la Cruz; Badi El Osta; Zhijun Li; Bianca Calderon; J Lynn Palmer; Eduardo Bruera
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

4.  A survey on physician knowledge and attitudes towards clinical use of morphine for cancer pain treatment in China.

Authors:  Su Yanjun; Wang Changli; Weng Ling; Jennifer Catherine Ai-Lian Woo; Kwauk Sabrina; Liu Chang; Zhang Lei
Journal:  Support Care Cancer       Date:  2009-11-10       Impact factor: 3.603

5.  A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio.

Authors:  D W Boulton; P Arnaud; C L DeVane
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

6.  A Conformationally Gated Model of Methadone and Loperamide Transport by P-Glycoprotein.

Authors:  Morgan E Gibbs; Laura A Wilt; Kaitlyn V Ledwitch; Arthur G Roberts
Journal:  J Pharm Sci       Date:  2018-02-28       Impact factor: 3.534

7.  Efficacy and Safety of Methadone as a Second-Line Opioid for Cancer Pain in an Outpatient Clinic: A Prospective Open-Label Study.

Authors:  Josep Porta-Sales; Cristina Garzón-Rodríguez; Christian Villavicencio-Chávez; Silvia Llorens-Torromé; Jesús González-Barboteo
Journal:  Oncologist       Date:  2016-06-15

8.  Opioid Rotation in Cancer Pain Treatment.

Authors:  Michael Schuster; Oliver Bayer; Florian Heid; Rita Laufenberg-Feldmann
Journal:  Dtsch Arztebl Int       Date:  2018-03-02       Impact factor: 5.594

9.  The role of methadone in opioid rotation-a Polish experience.

Authors:  Wojciech Leppert
Journal:  Support Care Cancer       Date:  2008-11-29       Impact factor: 3.603

10.  Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice.

Authors:  Jun-Sheng Wang; Ying Ruan; Robin M Taylor; Jennifer L Donovan; John S Markowitz; C Lindsay DeVane
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.